Bioventus Inc.BVSEarnings & Financial Report
Bioventus Inc. is a global medical technology company specializing in orthobiologic solutions. It develops and commercializes products supporting bone and joint healing, musculoskeletal pain management, and regenerative care for patients. Its offerings serve orthopedic clinicians, physical therapists, and patients across North America, Europe, and Asia Pacific, with core segments covering surgical orthobiologics and non-surgical pain relief solutions.
Revenue
$153.6M
Gross Profit
$102.7M
Operating Profit
$7.7M
Net Profit
$-388.0K
Gross Margin
66.8%
Operating Margin
5.0%
Net Margin
-0.3%
YoY Growth
N/A
EPS
$0.00
Bioventus Inc. Q4 FY2024 Financial Summary
Bioventus Inc. reported revenue of $153.6M for Q4 FY2024, with a net profit of $-388.0K (-0.3% margin). Cost of goods sold was $51.0M, operating expenses totaled $95.0M.
Key Financial Metrics
| Total Revenue | $153.6M |
|---|---|
| Net Profit | $-388.0K |
| Gross Margin | 66.8% |
| Operating Margin | 5.0% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Bioventus Inc. Q4 FY2024 revenue of $153.6M breaks down across 4 segments, led by Pain Treatments at $62.8M (40.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pain Treatments | $62.8M | 40.9% |
| Surgical Solutions | $46.4M | 30.2% |
| Restorative Therapies | $26.0M | 16.9% |
| Other | $18.4M | 12.0% |
Bioventus Inc. Revenue by Segment — Quarterly Trend
Bioventus Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Pain Treatments and Surgical Solutions) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Pain Treatments | $71.1M | $60.0M | $64.4M | $52.7M |
| Surgical Solutions | $48.9M | $45.0M | $45.7M | $40.8M |
| Restorative Therapies | $19.5M | $18.4M | $18.6M | $17.0M |
| Other | $18.4M | $15.3M | $18.9M | $13.4M |
Bioventus Inc. Annual Revenue by Year
Bioventus Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $568.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $568.1M |
| 2024 | $573.3M |
Bioventus Inc. Quarterly Revenue & Net Profit History
Bioventus Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $157.9M | +2.8% | $14.8M | 9.3% |
| Q3 FY2025 | $138.7M | -0.2% | $3.2M | 2.3% |
| Q2 FY2025 | $147.7M | -2.4% | $7.5M | 5.1% |
| Q1 FY2025 | $123.9M | -4.3% | $-2.6M | -2.1% |
| Q4 FY2024 | $153.6M | — | $-388.0K | -0.3% |
| Q3 FY2024 | $139.0M | +15.0% | $-5.2M | -3.7% |
| Q2 FY2024 | $151.2M | +27.0% | $-25.7M | -17.0% |
| Q1 FY2024 | $129.5M | — | $-4.9M | -3.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $129.5M | $151.2M | $139.0M | $153.6M | $123.9M | $147.7M | $138.7M | $157.9M |
| YoY Growth | N/A | 27.0% | 15.0% | N/A | -4.3% | -2.4% | -0.2% | 2.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $794.2M | $792.2M | $769.5M | $728.0M | $691.4M | $706.8M | $701.6M | $683.6M |
| Liabilities | $576.8M | $603.1M | $582.7M | $542.4M | $505.9M | $505.5M | $494.3M | $455.1M |
| Equity | $171.3M | $150.9M | $148.7M | $147.9M | $148.1M | $161.2M | $166.1M | $184.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.0M | $15.2M | $10.3M | $19.3M | $-19.3M | $25.9M | $30.1M | $38.0M |